Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03939897
Title Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

Her2-receptor negative breast cancer


Abemaciclib + Fulvestrant

Abemaciclib + Copanlisib + Fulvestrant

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.